Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2004;44:826-831
Published online before print November 8, 2004, doi: 10.1161/01.HYP.0000148458.03202.48
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
44/6/826    most recent
01.HYP.0000148458.03202.48v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xie, Z.
Right arrow Articles by Singh, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xie, Z.
Right arrow Articles by Singh, K.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Related Collections
Right arrow Remodeling
Right arrow Hypertrophy

(Hypertension. 2004;44:826.)
© 2004 American Heart Association, Inc.


Scientific Contributions

Osteopontin Modulates Myocardial Hypertrophy in Response to Chronic Pressure Overload in Mice

Zhonglin Xie; Mahipal Singh; Krishna Singh

From the Department of Physiology, James H. Quillen College of Medicine, James H. Quillen Veterans Affairs Medical Center, East Tennessee State University, Johnson City, Tenn.

Correspondence to Krishna Singh, PhD, Department of Physiology, James H. Quillen College of Medicine, East Tennessee State University, PO Box 70576, Johnson City, TN 37614. E-mail singhk{at}mail.etsu.edu

Osteopontin (OPN) expression increases in the heart during hypertrophy and heart failure. Here, we studied the role of OPN in pressure overload–induced hypertrophy and analyzed the signaling pathways involved in hypertrophy. Aortic banding (AB) was performed in a group of wild-type (WT) and OPN knockout (KO) mice to induce pressure overload. Left ventricular (LV) structural and functional remodeling was studied 1 month after AB. AB increased OPN and ß1 integrin (a receptor for OPN) protein expression in WT-AB group. Hypertrophic response as measured by increased heart weight-to-body weight ratio and myocyte cross-sectional area was significantly increased in WT-AB and KO-AB groups when compared with their respective shams. However, the increase was significantly higher in WT-AB. Re-expression of atrial natriuretic factor was only detected in WT-AB group. LV end-diastolic pressure-volume curve obtained using Langendorff perfusion analysis exhibited a leftward shift in WT-AB group, not in KO-AB. LV-developed pressures measured over a range of LV volumes were significantly increased in WT-AB, not in KO-AB mice. Increased phosphorylation of c-Jun N-terminal kinases, p38 kinase, Akt, and glycogen synthase kinase-3ß was significantly higher in WT-AB when compared with KO-AB group. Increased OPN expression may play an essential role in modulating compensatory cardiac hypertrophy in response to chronic pressure overload.


Key Words: heart • hypertrophy • kinase




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Q. Yu, R. Vazquez, E. V. Khojeini, C. Patel, R. Venkataramani, and D. F. Larson
IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H76 - H85.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
S. M. Swift, B. R. Gaume, K. M. Small, B. J. Aronow, and S. B. Liggett
Differential coupling of Arg- and Gly389 polymorphic forms of the {beta}1-adrenergic receptor leads to pathogenic cardiac gene regulatory programs
Physiol Genomics, September 17, 2008; 35(1): 123 - 131.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
M. Rosenberg, C. Zugck, M. Nelles, C. Juenger, D. Frank, A. Remppis, E. Giannitsis, H. A. Katus, and N. Frey
Osteopontin, a New Prognostic Biomarker in Patients With Chronic Heart Failure
Circ Heart Fail, May 1, 2008; 1(1): 43 - 49.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
F. G. Spinale
Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function
Physiol Rev, October 1, 2007; 87(4): 1285 - 1342.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Oka, J. Xu, R. A. Kaiser, J. Melendez, M. Hambleton, M. A. Sargent, A. Lorts, E. W. Brunskill, G. W. Dorn II, S. J. Conway, et al.
Genetic Manipulation of Periostin Expression Reveals a Role in Cardiac Hypertrophy and Ventricular Remodeling
Circ. Res., August 3, 2007; 101(3): 313 - 321.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. Subramanian, P. Krishnamurthy, K. Singh, and M. Singh
Lack of osteopontin improves cardiac function in streptozotocin-induced diabetic mice
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H673 - H683.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. A. Arias-Loza, K. Hu, A. Schafer, J. Bauersachs, T. Quaschning, J. Galle, V. Jazbutyte, L. Neyses, G. Ertl, K.-H. Fritzemeier, et al.
Medroxyprogesterone Acetate But Not Drospirenone Ablates the Protective Function of 17{beta}-Estradiol in Aldosterone Salt-Treated Rats
Hypertension, November 1, 2006; 48(5): 994 - 1001.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
K. C. Bilchick, S. K. Saha, E. Mikolajczyk, L. Cope, W. J. Ferguson, W. Yu, S. Girouard, and D. A. Kass
Differential regional gene expression from cardiac dyssynchrony induced by chronic right ventricular free wall pacing in the mouse
Physiol Genomics, September 14, 2006; 26(2): 109 - 115.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. M. Deschamps and F. G. Spinale
Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation
Cardiovasc Res, February 15, 2006; 69(3): 666 - 676.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Graf and P. Stawowy
Osteopontin: A Protective Mediator of Cardiac Fibrosis?
Hypertension, December 1, 2004; 44(6): 809 - 810.
[Full Text] [PDF]